Zydus Lifesciences Limited has informed the Exchange regarding a press release dated November 11, 2025, titled "Zydus receives approval from China s NMPA for Venlafaxine Extended-Release Capsules, 75 mg and 150 mg".
ZYDUSLIFE · price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
Awaiting price reaction for this filing.
Zydus Lifesciences has received approval from China's National Medical Products Administration (NMPA) for Venlafaxine Extended-Release Capsules in 75 mg and 150 mg strengths. Venlafaxine ER is used to treat depression and anxiety disorders. This approval allows Zydus to market and sell the product in the Chinese market. The move expands Zydus's footprint in one of the world's largest pharmaceutical markets. Specific revenue impact and launch timeline details were not disclosed in the filing.
Positive for Zydus as it opens a new revenue stream in China, though the immediate financial impact is likely modest since no order size or revenue guidance was provided. This strengthens the company's regulated market portfolio.